Ask AI
ProCE Banner Activity

TROP2 ADCs for Advanced HR-Positive/HER2-Negative and Triple-Negative Cancers: Translating New Data into Practice

Clinical Thought

Explore pivotal phase III evidence supporting recent updated regulatory indications for TROP2 ADCs in metastatic HR-positive/HER2-negative and triple-negative breast cancer, with a focus on how new efficacy and safety data inform treatment selection. Learn about expert considerations when selecting therapy in the first-line and later-line settings based on eligibility for immunotherapy and the adverse event profile of available TROP-targeted ADCs. Finally, learn how to anticipate potential adverse event challenges limiting therapy persistence, as well as how to mitigate them and incorporate supportive care approaches.

Released: August 25, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Gilead Sciences, Inc.

Target Audience

This educational activity is intended for European oncologists and other healthcare professionals who care for patients with metastatic TNBC or HR+/HER2− MBC

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize current and emerging clinical evidence supporting the use of TROP2-directed antibody–drug conjugates in metastatic TNBC or HR+/HER2− MBC with a focus on best practices in Europe

  • Identify appropriate candidates with metastatic TNBC or HR+/HER2− MBC for treatment with TROP2-directed ADCs based on disease characteristics, prior therapy exposure, comorbidities, and patient goals

  • Implement evidence-based strategies for monitoring, prevention, and management of adverse events associated with TROP2-directed ADCs in patients with metastatic TNBC or HR+/HER2− MBC to support treatment continuity and patient quality of life

  • Evaluate the clinical implications of evolving data on novel and combination approaches involving ADCs and consider how ongoing research may reshape future treatment algorithms in metastatic TNBC or HR+/HER2− MBC

Financial Disclosures

Primary Author

Peter Schmid, MD, PhD, FRCP: consultant/advisor/speaker: AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Roche.